ProQR Therapeutics NV
NASDAQ:PRQR
ProQR Therapeutics NV
Operating Expenses
ProQR Therapeutics NV
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Operating Expenses
-€44m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
AEX:PHARM
|
Operating Expenses
-$241.9m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-34%
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Expenses
-$261.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-21%
|
|
argenx SE
XBRU:ARGX
|
Operating Expenses
-$1.5B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
Merus NV
NASDAQ:MRUS
|
Operating Expenses
-$204.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Operating Expenses
-€101.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ProQR Therapeutics NV's Operating Expenses?
Operating Expenses
-44m
EUR
Based on the financial report for Mar 31, 2024, ProQR Therapeutics NV's Operating Expenses amounts to -44m EUR.
What is ProQR Therapeutics NV's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
1%
Over the last year, the Operating Expenses growth was 28%. The average annual Operating Expenses growth rates for ProQR Therapeutics NV have been 2% over the past three years , 1% over the past five years .